Alessandro Riva Sells 212 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Director Alessandro Riva sold 212 shares of the firm’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $309.51, for a total transaction of $65,616.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Trading Down 3.1%

ONC opened at $290.58 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The company’s 50 day simple moving average is $301.92 and its two-hundred day simple moving average is $320.91. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $239.25 and a 1-year high of $385.22. The firm has a market capitalization of $31.88 billion, a price-to-earnings ratio of 65.01 and a beta of 0.50.

BeOne Medicines (NASDAQ:ONC) last released its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The business had revenue of $1.51 billion for the quarter. Analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 5.65 EPS for the current fiscal year.

Institutional Trading of BeOne Medicines

Several institutional investors have recently made changes to their positions in ONC. EFG International AG purchased a new stake in shares of BeOne Medicines during the 4th quarter valued at approximately $25,000. Leonteq Securities AG purchased a new stake in shares of BeOne Medicines during the 4th quarter valued at approximately $35,000. Daiwa Securities Group Inc. purchased a new stake in shares of BeOne Medicines during the 2nd quarter valued at approximately $35,000. CWM LLC increased its holdings in BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after purchasing an additional 39 shares during the last quarter. Finally, Group One Trading LLC acquired a new stake in BeOne Medicines in the 4th quarter valued at approximately $61,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Wells Fargo & Company assumed coverage on shares of BeOne Medicines in a research note on Monday, May 4th. They issued an “overweight” rating and a $400.00 target price on the stock. Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Guggenheim raised their target price on shares of BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Leerink Partners raised their target price on shares of BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a research note on Friday, May 15th. Finally, Wolfe Research assumed coverage on shares of BeOne Medicines in a research note on Friday, March 27th. They issued an “outperform” rating and a $340.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $389.15.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.